Skip to content

    Supriya Lifesci.

    SUPRIYA
    Healthcare·10 Feb 2026
    Management Summary

    Supriya Lifescience reported a solid Q3 FY26 with 11% YoY revenue growth to ₹206 crores and a strong 35% EBITDA margin. Exports remained a significant contributor, and new product launches are progressing. The Ambernath facility is set for capitalization in Q4 FY26, though its EU inspection is delayed. Management remains confident in achieving its FY26 revenue guidance and long-term targets, emphasizing strategic focus on regulated markets and backward integration.

    Highlights

    6

    • Revenue from operations grew 11% YoY to ₹206 crores in Q3 FY26, driven by robust demand.

    • EBITDA margin maintained at 35% for Q3 FY26, reflecting strong execution and focus on high-margin niche offerings.

    • PAT margin stood at 24.1% for Q3 FY26.

    • Exports contributed 82% of Q3 revenues, with healthy growth in LatAm (24% of revenues) and North America (6%).

    • Successfully launched a key cardiovascular product and an ADHD product in Q3 FY26, with a liquid anaesthetics product also commercialized.

    • Ambernath facility is ready for capitalization in Q4 FY26, a key milestone for the CDMO segment.

    Concerns

    3

    • EBITDA growth for 9M FY26 was only 1.7% YoY, despite 8% revenue growth, indicating some margin pressure over the longer period.

    • EU CGMP inspection for the Ambernath facility has been delayed to Q1 next financial year due to 'low manpower' at the EU authority, impacting regulatory approvals and market traction.

    • Ambiguity in end-users accepting new pricing for ATS-8 in the domestic market was noted.

    Key financials

    Metrics

    10

    Periods

    2

    Q3 FY26

    5
    • Revenue
      ₹206 Cr
      YoY+11%
    • EBITDA
      ₹72 Cr
      YoY+9%
    • EBITDA Margin
      35%
    • PAT
      ₹50 Cr
    • PAT Margin
      24.1%

    9M FY26

    5
    • Revenue
      ₹551 Cr
      YoY+8%
    • EBITDA
      ₹196 Cr
      YoY+1.7%
    • EBITDA Margin
      36%
    • PAT
      ₹135 Cr
    • PAT Margin
      25%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹28 crores this quarter · ₹86 crores (FY26) planned

    Debt

    Debt disclosed

    Guidance & targets

    10
    CategoryTargetPriority
    Revenue
    Annual Revenue Growth
    20%
    		High
    Revenue
    Revenue Milestone
    ₹1,000 crores
    		High
    Revenue
    Ambernath Facility Revenue Contribution
    2.5x capital value
    		High
    Revenue
    DSM Project Revenue Contribution
    ₹60 crores
    		Medium
    Revenue
    New Product Contribution
    10%
    		Medium
    Revenue
    CDMO/CMO + New Products Contribution
    20%
    		High
    Margin
    EBITDA Margin
    33-35%
    		High
    Product Launches
    New Product Launches
    3-4 products
    		High
    Volume
    ATS-8 Volume
    250-300 tons
    		High
    Profitability
    Ambernath Facility EBITDA Positive
    EBITDA positive
    		Medium

    Q4 FY26 Revenue Achievement

    Next quarter (Q4 FY26 results)
    Current₹551 crores (9M FY26)
    Target₹284 crores (Q4 FY26) to meet 20% annual growth

    Why it matters

    Meeting the Q4 revenue target is essential for the company to achieve its stated 20% annual revenue growth guidance for FY26.

    So, I just had a follow-up question on the previous participant. You mentioned that you'll still be able to achieve the 20% annual revenue growth for FY26. So, to do that, we will need INR284 crores of revenue in Q4 FY26.

    How to verify

    key_financials.metrics[label='Revenue (Q4 FY26)']

    Risks & concerns

    3
    RiskSeverity

    Delay in EU CGMP inspection for Ambernath facility

    The EU CGMP inspection for the Ambernath facility, crucial for regulatory approval and market access, has been delayed to Q1 next financial year due to 'low manpower' at the EU authority. — Management acknowledged

    medium

    Ambiguity in market acceptance of new ATS-8 pricing

    There is still ambiguity among end-users regarding the acceptance of the new pricing for ATS-8, particularly in the domestic Indian market. — Management acknowledged

    medium

    Regulatory approval timelines for new products and facilities

    The pace of new product scale-up and full revenue potential from facilities like Ambernath are contingent on timely regulatory approvals, which can take 2-3 years for new products in regulated markets. — Management acknowledged

    medium

    Q&A highlights

    8

    “Yes, we still have visibility over that 300 ton, and we are very confident that after the successful scale up, which happened in Q3, we will be able to start penetrating into that market and start getting the volume in the coming few quarters.”

    Confirms continued visibility for a key product and outlines the timeline for market entry and revenue contribution.

    asked by Tarun Krishna

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Supriya Lifescience reported a revenue from operations of ₹206 crores for Q3 FY26, marking an 11% year-on-year growth. This was driven by robust demand across its product portfolio. The company achieved a strong EBITDA margin of 35% and a PAT margin of 24.1% for the quarter, with EBITDA at ₹72 crores and PAT at ₹50 crores. For the nine months ended December 31, 2025, revenue stood at ₹551 crores (8% YoY growth) and EBITDA at ₹196 crores (1.7% YoY growth).

    02

    Export Performance and Geographic Focus

    Exports continued to be a primary growth driver, accounting for 82% of Q3 revenues. The LatAm region showed healthy growth, contributing 24% of total revenues, while North America contributed 6%. Both regions saw an increase in their overall revenues. The company aims to scale its presence in regulated markets and reinforce its competitive position through backward integration and a diverse product portfolio.

    03

    New Product Launches and Pipeline

    Supriya Lifescience successfully launched a key cardiovascular product in Q3 FY26, which is expected to contribute meaningfully in Q4 FY26. An ADHD product was also launched, with scaling anticipated in coming quarters. The liquid anaesthetics product has been commercialized with steady monthly supplies. Development activities for a contrast media product are progressing as planned, and the company intends to introduce 3-4 new products annually.

    04

    Ambernath Facility Update and CDMO Segment

    The Ambernath facility is ready for capitalization and is a key milestone for the CDMO segment, with capitalization expected in Q4 FY26. Total capex for Ambernath is estimated between ₹140-160 crores, and it is projected to generate revenue at 2.5 times its capital value. Commercial revenues from Ambernath are expected from Q4 FY26, with the facility potentially becoming EBITDA positive by Q3 FY27. However, the EU CGMP inspection for Ambernath has been delayed to Q1 next financial year due to manpower limitations at the EU authority.

    05

    Backward Integration and Cost Structure

    Backward integration initiatives continued to advance, contributing to 74% of Q3 revenues and strengthening the company's cost structure. The ATS-3 to ATS-5 backward integration process has been developed and is expected to start commercially by next month (March 2026). This focus on backward integration, along with high-margin niche offerings, supports the company's operational efficiency.

    06

    Strategic Outlook and Long-Term Targets

    Management reiterated its guidance of approximately 20% annual revenue growth for FY26 and EBITDA margins of 33-35%. The company remains on course for its ₹1,000 crores revenue milestone by FY27, supported by new launches, existing product scale-up, and the Ambernath facility. The combined contribution from new products and CDMO/CMO is targeted at 20% over the next two years. For ATS-8, the company aims to cater to 250-300 tons for quality-conscious customers in FY27.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.